论文部分内容阅读
目的评价卡培他滨联合奥沙利铂治疗III期结直肠癌的疗效与安全性。方法奥沙利铂120mg/m2,静脉点滴2h,第1天;卡培他滨2500mg/m2,分早晚2次口服,第1～14天,每3周为1个周期,重复2个周期以上。结果总有效率(CR+PR)为52.2%,不良反应主要表现为手足综合征,神经毒性,骨髓抑制,胃肠道反应,程度较轻,以I度、II度为主。结论卡培他滨联合奥沙利铂治疗III期结直肠癌疗效好,不良反应较轻,患者生活质量提高。
Objective To evaluate the efficacy and safety of capecitabine and oxaliplatin in the treatment of stage III colorectal cancer. Methods Oxaliplatin 120mg / m2, intravenous drip 2h, the first day; capecitabine 2500mg / m2, points twice daily morning and evening orally, the first to 14 days, every 3 weeks for a cycle of more than 2 cycles . Results The total effective rate (CR + PR) was 52.2%. Adverse reactions mainly manifested as hand-foot syndrome, neurotoxicity, myelosuppression and gastrointestinal reactions. Conclusion Capecitabine combined with oxaliplatin in the treatment of stage III colorectal cancer has good curative effect, less adverse reactions and improved quality of life.